Zomedica’s Dr. Bonnie Bragdon to Speak at AVMA Convention 2019 on Sunday, August 4
25 Juillet 2019 - 12:55PM
Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a
veterinary diagnostic and pharmaceutical company, today announced
Dr. Bonnie Bragdon, Vice President of Marketing and Veterinary
Affairs, will speak during two sessions at AVMA Convention 2019 on
Sunday, August 4, at the Walter E. Washington Convention Center in
Washington D.C.
Novel Application of Technology in Diagnostic Testing will take
place from 12:00 – 12:20 p.m. in the Convention’s Digital District.
The discussion will highlight the challenges veterinarians face in
diagnosing and managing canine cancer. Advancements and
applications of microfluidics for the detection of circulating
tumor cells in human and veterinary medicine will also be
featured.
Additionally, Dr. Bragdon will discuss Novel Applications of
Technology in Diagnostic Testing: How Cell Phones, Lasers, and
Inkjet Printers Will Lead to Advances in Practice from 5:00 – 5:50
p.m. on Sunday, August 4, in room 143BC.
The session will cover topics including the use of Raman
spectroscopy and bulk acoustic wave sensors in clinical
diagnostics. Raman spectroscopy has been used commercially in drug
production and biomedical research for decades. Dr. Bragdon will
focus on Zomedica’s application of Raman spectroscopy in pathogen
identification and antibiotic stewardship. Additionally, Dr.
Bragdon will discuss how bulk acoustic wave sensors can improve
immunoassay accuracy in veterinary medicine. Immunoassays are
widely used in veterinary medicine to diagnose diseases. Bulk
acoustic resonator technology is now cost-effective and can be used
to drive improvements in immunoassay accuracy at the point-of-care.
Currently, optical and electrical sensors are used, with
limitations in performance, to measure binding events that provide
results for clinical decision making.
About ZomedicaBased in Ann Arbor,
Michigan, Zomedica (NYSE American: ZOM) (TSX-V: ZOM) is a
veterinary diagnostic and pharmaceutical company creating products
for companion animals (canine, feline and equine) by focusing on
the unmet needs of clinical veterinarians. Zomedica’s product
portfolio will include novel diagnostics and innovative
therapeutics that emphasize patient health and practice health.
With a team that includes clinical veterinary professionals, it is
Zomedica’s mission to give veterinarians the opportunity to lower
costs, increase productivity, and grow revenue while better serving
the animals in their care. For more information, visit
www.ZOMEDICA.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://www.facebook.com/zomedica/
- Twitter: https://twitter.com/zomedica
Investor Relations Contact: Shameze Rampertab,
CPA, CAsrampertab@zomedica.com +1 647.283.3630 PCG Advisory Group
Kirin Smith, COOksmith@pcgadvisory.com +1 646.863.6519
Media Contact: Christy Penkacpenka@zomedica.com+1
734.369.2555
Zomedica Pharmaceuticals (TSXV:ZOM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Zomedica Pharmaceuticals (TSXV:ZOM)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
Real-Time news about Zomedica Pharmaceuticals Corp (TSX Venture Exchange): 0 recent articles
Plus d'articles sur